Deciphering the Pathways to PARP Sensitivity in Pancreatic Cancer.

Tsang, Erica S; Gallinger, Steven

Tsang, Erica S; Gallinger, Steven.

Afiliação

Tsang ES; Princess Margaret Cancer Centre, University of Toronto, Toronto, Ontario, Canada.
Gallinger S; Ontario Institute for Cancer Research, Toronto, Ontario, Canada.

Clin Cancer Res ; 29(24): 5005-5007, 2023 12 15.

Article em En | MEDLINE | ID: mdl-37787975

RESUMO

A recent article analyzed paired cell-free DNA among patients with platinum-sensitive BRCA- or PALB2-mutated pancreatic cancer who received maintenance olaparib. Reversion mutations were linked with worse outcomes. These types of paired correlative studies are needed to improve our understanding of drug resistance and guide future clinical trials. See related article by Brown et al., p. 5207.

Assuntos

Antineoplásicos; Neoplasias Ovarianas; Neoplasias Pancreáticas; Feminino; Humanos; Antineoplásicos/uso terapêutico; Inibidores de Poli(ADP-Ribose) Polimerases/uso terapêutico; Neoplasias Ovarianas/genética; Proteína BRCA2/genética; Ftalazinas/uso terapêutico; Neoplasias Pancreáticas/tratamento farmacológico; Neoplasias Pancreáticas/genética

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Neoplasias Ovarianas / Neoplasias Pancreáticas / Antineoplásicos Tipo de estudo: Diagnostic_studies Limite: Female / Humans Idioma: En Ano de publicação: 2023 Tipo de documento: Article

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google